SML0288
Nepafenac
≥98% (HPLC)
别名:
2-Amino-3-benzoyl-benzeneacetamide, AHR 9434, AL 6515
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H14N2O2
化学文摘社编号:
分子量:
254.28
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
Nepafenac, ≥98% (HPLC)
InChI
1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
SMILES string
NC(=O)Cc1cccc(c1N)C(=O)c2ccccc2
InChI key
QEFAQIPZVLVERP-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
faintly yellow to dark yellow
solubility
DMSO: ≥5 mg/mL
storage temp.
room temp
Quality Level
Gene Information
human ... PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.
Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) used in opthamology.
Nepafenac, a prodrug of amfenac, is used in the treatment of diabetic retinopathy. It is metabolized to its active form through intraocular enzymatic hydrolysis. Nepafenac has a molecular weight of 254.28 kDa and effectively penetrates through the cornea. Its molecule structure enables nepafenac to possess better permeability. Nepafenac has a low inhibitory effect on cyclooxygenase.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology
Kern TS, et al.
Diabetes, 56(2), 373-379 (2007)
Retinal Pharmacotherapeutics: Retinal Pharmacotherapeutics (2015)
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac
Walters T, et al.
Journal of Cataract and Refractive Surgery, 33(9), 1539-1545 (2007)
Eric Chen et al.
Clinical ophthalmology (Auckland, N.Z.), 4, 1249-1252 (2010-12-15)
The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macular degeneration. This was a retrospective, consecutive case series of patients with
Haley Shelley et al.
AAPS PharmSciTech, 19(6), 2554-2563 (2018-06-28)
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID), currently only available as 0.1% ophthalmic suspension (Nevanac®). This study utilized hydroxypropyl-β-cyclodextrin (HPBCD) to increase the water solubility and trans-corneal permeation of nepafenac. The nepafenac-HPBCD complexation in the liquid and solid states were
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持